These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 23924146)

  • 1. Delayed allograft inflammation following alemtuzumab induction for kidney transplantation.
    Heilman RL; Khamash HA; Smith ML; Chakkera HA; Moss AA; Reddy KS
    Clin Transplant; 2013; 27(5):772-80. PubMed ID: 23924146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
    Saull HE; Enderby CY; Gonwa TA; Wadei HM
    Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin.
    Reddy KS; Devarapalli Y; Mazur M; Hamawi K; Chakkera H; Moss A; Mekeel K; Post D; Heilman R; Mulligan D
    Transplant Proc; 2010; 42(6):2006-8. PubMed ID: 20692393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial.
    Bösmüller C; Ollinger R; Sieb M; Weissenbacher A; Schneeberger S; Pratschke J; Margreiter R
    Ann Transplant; 2012 Dec; 17(4):45-51. PubMed ID: 23274323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
    Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab induction in deceased donor kidney transplantation.
    Huang E; Cho YW; Hayashi R; Bunnapradist S
    Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
    Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
    Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depleting Antibody Induction and Kidney Transplant Outcomes: A Paired Kidney Analysis.
    Sampaio MS; Chopra B; Sureshkumar KK
    Transplantation; 2017 Oct; 101(10):2527-2535. PubMed ID: 28475563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft.
    Grinyó JM; Gil-Vernet S; Seron D; Hueso M; Fulladosa X; Cruzado JM; Moreso F; Fernandez A; Torras J; Riera L; Castelao AM; Alsina J
    Nephrol Dial Transplant; 1998 Oct; 13(10):2601-4. PubMed ID: 9794567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab induction in renal transplantation.
    Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
    N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of steroid-free low concentration calcineurin inhibitor maintenance immunosuppression regimen on renal allograft histopathology and function.
    Nainani N; Patel N; Tahir N; Kumar R; Weber-Shrikant E; Gundroo AA; Murray BM; Tornatore KM; Blessios GA; Venuto RC
    Nephrol Dial Transplant; 2012 May; 27(5):2077-83. PubMed ID: 22058172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression.
    Sureshkumar KK; Thai NL; Hussain SM; Ko TY; Marcus RJ
    Transplantation; 2012 Apr; 93(8):799-805. PubMed ID: 22290269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial.
    Welberry Smith MP; Cherukuri A; Newstead CG; Lewington AJ; Ahmad N; Menon K; Pollard SG; Prasad P; Tibble S; Giddings E; Baker RJ
    Transplantation; 2013 Dec; 96(12):1082-8. PubMed ID: 24056618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and safety between rabbit anti-thymocyte globulin and anti-T lymphocyte globulin in kidney transplantation from donation after cardiac death: a retrospective cohort study.
    Chen GD; Lai XQ; Ko DS; Qiu J; Wang CX; Han M; Li J; Huang G; He XS; Chen LZ
    Nephrology (Carlton); 2015 Aug; 20(8):539-43. PubMed ID: 25808082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
    Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.